{
    "clinical_study": {
        "@rank": "146501", 
        "brief_summary": {
            "textblock": "The objective of this trial is to determine the maximum tolerated dose and the toxicities of\n      paclitaxel given as a short hour infusion in children with refractory malignancy."
        }, 
        "brief_title": "Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy", 
        "completion_date": "July 2000", 
        "condition": "Neoplasms", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Paclitaxel is an active antitumor agent that has demonstrated a broad range of activity in\n      preclinical and clinical studies.  The optimal dose and schedule has not yet been determined\n      in either adults or children.  The objective of this trial is to determine the maximum\n      tolerated dose and the toxicities of paclitaxel given as a short hour infusion in children\n      with refractory malignancy.  In addition, the pharmacokinetics of paclitaxel given in this\n      way will be studied and both model-dependent and model-independent parameters will be\n      determined."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n        Histologically confirmed cancer (including leukemia) that is: Refractory to standard\n        therapy (objective disease progression required) OR For which no standard therapy exists\n        and patient is ineligible for  potentially curative surgery.\n\n        PRIOR/CONCURRENT THERAPY:\n\n        Recovery from the toxic effects of prior therapy required.\n\n        Biologic Therapy: Not specified.\n\n        Chemotherapy: No prior taxanes. At least 3 weeks since myelosuppressive therapy (6 weeks\n        since nitrosourea).\n\n        Endocrine Therapy: Not specified.\n\n        Radiotherapy: Prior extensive craniospinal or pelvic irradiation allowed.\n\n        Surgery: Ineligible for potential curative surgery.\n\n        Other: Prior bone marrow transplant allowed.\n\n        PATIENT CHARACTERISTICS:\n\n        Age:  Over 1 to 21;\n\n        Performance status: ECOG 0-2;\n\n        Life expectancy: At least 8 weeks.\n\n        Hematopoietic:  (except with leukemia, bone marrow involvement, history of bone marrow\n        transplantation, or extensive prior radiotherapy).\n\n        Absolute granulocyte count at least 1,500/mm(3);\n\n        Platelet count at least 100,000/mm(3);\n\n        Hemoglobin at least 8.0 g/dL.\n\n        Hepatic:\n\n        Bilirubin no greater than 1.5 mg/dL;\n\n        AST less than 2 times normal.\n\n        Renal:\n\n        Creatinine no greater than 1.5 mg/dL OR;\n\n        Creatinine clearance at least 60 mL/min per square meter.\n\n        OTHER:\n\n        No concurrent anticonvulsant therapy.\n\n        No grade 2 or worse neuropathy.\n\n        No significant systemic illness (e.g., infection) that could compromise drug excretion or\n        confuse assessment of toxicity.\n\n        Not pregnant or nursing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "25", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001387", 
            "org_study_id": "940204", 
            "secondary_id": "94-C-0204"
        }, 
        "intervention": {
            "intervention_name": "paclitaxel", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "keyword": [
            "Paclitaxel", 
            "Pediatric", 
            "Pharmacokinetics", 
            "Phase I", 
            "Toxicity"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I and Pharmacokinetic Trial of Paclitaxel (Taxol) Given as a 3-Hour Infusion in Pediatric Patients With Refractory Malignancy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "8102014", 
                "citation": "Rowinsky EK, Donehower RC. The clinical pharmacology of paclitaxel (Taxol). Semin Oncol. 1993 Aug;20(4 Suppl 3):16-25. Review."
            }, 
            {
                "PMID": "7901342", 
                "citation": "Huizing MT, Keung AC, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes IM, Dubbelman AC, Pinedo HM, Beijnen JH. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol. 1993 Nov;11(11):2127-35."
            }, 
            {
                "PMID": "7505830", 
                "citation": "Kohn EC, Sarosy G, Bicher A, Link C, Christian M, Steinberg SM, Rothenberg M, Adamo DO, Davis P, Ognibene FP, et al. Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst. 1994 Jan 5;86(1):18-24."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001387"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "September 1994", 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1999"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}